A Study of ABM-1310 in Patients With BRAF V600-Mutant Relapsed and Drug Resistant Primary Malignant Brain Tumors
Clinical trial NCT05892653 · TERMINATED
Trial details
- NCT number
- NCT05892653
- Sponsor
- ABM Therapeutics Shanghai Company Limited
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-06-30
- Primary completion
- 2024-08-27
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.